Marguerite Bernard
Internal Medicine · Bronx, NYNPI 1952374613
Payments from drug & device makers
Across 569 payments — averaging $37.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$4K
- Viiv Healthcare Company$4K
- Gilead$3K
- Johnson & Johnson$3K
- Janssen Products, LP$2K
- Boehringer Ingelheim$1K
- plus $5K from 22 others
What the payments were for
- Food & beverage$21,574100%
- Education$420%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 87 | $4,142 |
| Viiv Healthcare Company | 101 | $3,704 |
| Gilead | 54 | $2,570 |
| Johnson & Johnson | 117 | $2,557 |
| Janssen Products, LP | 19 | $2,223 |
| Boehringer Ingelheim | 9 | $1,069 |
| EMD Serono, Inc. | 52 | $994 |
| Merck | 33 | $937 |
| Medtronic | 17 | $500 |
| Lilly USA, LLC | 13 | $397 |
| GSK | 9 | $394 |
| Theratechnologies Inc. | 16 | $393 |
| AstraZeneca | 3 | $375 |
| Amarin Pharma, Inc. | 6 | $343 |
| Bayer | 3 | $266 |
| AbbVie | 8 | $231 |
| Sanofi-aventis U.S. LLC | 7 | $146 |
| Dynavax Technologies Corporation | 4 | $138 |
| Dexcom, Inc. | 2 | $61 |
| Janssen Scientific Affairs, LLC | 1 | $25 |
| IBSA Pharma Inc. | 1 | $24 |
| Shield Therapeutics Inc | 1 | $23 |
| Mylan Institutional Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Intercept Pharmaceuticals, Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Pfizer | 1 | $15 |
| Melinta Therapeutics, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,616 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 165 | $261,922 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 38 | $146,971 |
| TrulicityDulaglutide | 89 | $146,046 |
| JanuviaSitagliptin Phosphate | 90 | $83,434 |
| JardianceEmpagliflozin | 57 | $77,786 |
| RybelsusSemaglutide | 52 | $76,767 |
| DovatoDolutegravir Sodium/Lamivudine | 26 | $75,909 |
| JulucaDolutegravir/Rilpivirine | 14 | $70,812 |
| VascepaIcosapent Ethyl | 59 | $36,270 |
| LinzessLinaclotide | 49 | $34,134 |
| TradjentaLinagliptin | 30 | $28,755 |
| EliquisApixaban | 41 | $28,348 |
| MounjaroTirzepatide | 17 | $21,829 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $19,631 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 65 | $18,289 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $4,142 | $338,689217 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $397 | $167,875106 claims |
| GileadBiktarvy | $2,570 | $146,97138 claims |
| Viiv Healthcare CompanyDovato, Juluca | $3,704 | $146,72040 claims |
| Boehringer IngelheimJardiance, Tradjenta | $1,069 | $106,54187 claims |
| MerckJanuvia, Janumet | $937 | $97,249104 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta, Arnuity Ellipta, Shingrix | $394 | $58,541113 claims |
| AbbVieLinzess | $231 | $34,13449 claims |
| PfizerEliquis | $15 | $28,34841 claims |
| AstraZenecaSymbicort | $375 | $10,73025 claims |
| Johnson & JohnsonXarelto | $2,557 | $8,37212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Bronx
- Benjamin GartrellBronx$6.3M
- David SteinBronx$2.4M
- Haiying ChengBronx$1.7M
- Jason LeiderBronx$1.4M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.